Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

pected to begin in Q1 2009. It is anticipated that this Phase III development program will use the 125 (micro)g dose of microplasmin.

The decision to move into this Phase III program was in part based on the positive results from the Phase IIb MIVI III trial announced in late June. The MIVI III (MIVI III - Microplasmin for Vitreous Injection) trial showed that the most effective dose of microplasmin studied (125 (micro)g) was able to resolve the underlying disease in approximately 30% of patients without the need for a vitrectomy (surgical intervention). The encouraging results from this study were presented by Dr. George Williams (Beaumont Hospital, Michigan, USA) on June 28 at the World Ophthalmology Congress in Hong Kong.

The MIVI III trial was a Phase IIb, randomized, double-masked, placebo-controlled, dose-ranging trial that evaluated three doses of microplasmin (25, 75 and 125 (micro)g) versus placebo in 125 patients scheduled for vitrectomy. The patients were recruited at 19 centers across the United States. The trial was designed to assess the safety and efficacy of microplasmin intravitreal injection given 7 days prior to the patient's planned vitrectomy.

The study showed that microplasmin was well tolerated. The trial also showed a clear dose response curve with the highest dose (125 (micro)g) of microplasmin delivering the best results. In this group, 10 of the 32 patients receiving this dose of microplasmin had resolution of their underlying disease, and therefore did not need a vitrectomy for the indication for which they were being treated. This compares very favorably with the placebo group, where only 1 patient out of 31 achieved the same positive outcome. In addition, use of microplasmin was associated with a reduced amount and duration of suction needed to achieve a PVD in patients who progressed to surgical intervention, compared to placebo.

The visual acuity of all patients recruited into the study was also measured at
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... announced that management will present a company overview at the ... a.m. ET in Boston, MA. ... on the "Investors & Media" section of the Company,s website, ... Isis website within 48 hours and will be archived for ...
(Date:10/30/2014)... 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... conference call and live audio webcast on Thursday, November ... third quarter 2014 financial results. Interested participants ... (888) 347-1165 for domestic callers or (412) 902-4276 for ... under the investor relations section of the Regado website ...
(Date:10/30/2014)... DENVER (Oct. 29, 2014) – The severe flooding that ... have been less destructive if the bridges, roads and ... a new study from the University of Colorado Denver. ... of infrastructure," said Jimmy Kim, PhD, associate professor of ... and Applied Science and lead author the study. "There ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... HILL, N.C., Jan. 12, 2011 Cempra Pharmaceuticals ... of solithromycin (CEM-101), the first fluoroketolide antibiotic, at ... Advanced Research and Development Authority (BARDA) industry day ...   Solithromycin is a clinical-stage fluoroketolide ...
... Jan. 11, 2011 Fred Hutchinson Cancer Research Center ... Robert Eisenman, Ph.D., a molecular biologist and geneticist, have ... Advancement of Science, or AAAS. Election as a fellow ... peers. Brent, a member of the Hutchinson ...
... 2011 Regenicin, Inc. (OTC Bulletin Board: ... of regenerative cell therapies to restore the health of ... annual OneMedForum at the Sir Francis Drake Hotel in ... McCoy, will present Regenicin,s core business model and strategic ...
Cached Biology Technology:Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 2Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 3Roger Brent and Robert Eisenman Named AAAS Fellows 2Roger Brent and Robert Eisenman Named AAAS Fellows 3Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST 2
(Date:10/29/2014)... . Meiosis ... at the Max F. Perutz Laboratories (MFPL) of the ... dived into the process of meiosis in specific plant ... of the standard meiotic phases. The researchers describe the ... . , Meiosis is the two-step series of cell ...
(Date:10/29/2014)... of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen records ... into a human-readable text developed in manuscript within the ... to study the species distributions of ten Nearctic species ... is originally designed to support the generation and application ...
(Date:10/29/2014)... organisms in the living world compete with members ... in how much they invest into their competitive ... to get access to high-quality resources, while others ... of the lower-quality resources that are left over ... animal and human societies seems to fluctuate considerably ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Evolution of competitiveness 2Evolution of competitiveness 3
... Many plants produce toxic chemicals to protect themselves ... flower structures that prevent pollinators such as bees from ... evidence that flowering plants might also use chemical defences ... are published next week in the British Ecological Society,s ...
... MA - It is estimated that up to 10 ... of renal disease, with 450,000 patients with end stage ... Women,s Hospital, Massachusetts General Hospital and the University of ... be transplanted from one fish to another to regenerate ...
... students to ultimately provide quality patient care medical schools should ... the core disciplines of medicine, according to a study in ... College of Radiology ( www.jacr.org ). Physiology is the ... is vital that medical schools provide first-rate physiology education for ...
Cached Biology News:Secret life of bees now a little less secret 2Researchers unlock the potential for exploring kidney regeneration 2